Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $2.29 billion. The enterprise value is $2.01 billion.
| Market Cap | 2.29B |
| Enterprise Value | 2.01B |
Important Dates
The next estimated earnings date is Tuesday, April 30, 2024, before market open.
| Earnings Date | Apr 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 60.14 million shares outstanding. The number of shares has increased by 10.65% in one year.
| Shares Outstanding | 60.14M |
| Shares Change (YoY) | +10.65% |
| Shares Change (QoQ) | +2.34% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 115.37% |
| Float | 44.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.52 |
| Forward PS | 16.30 |
| PB Ratio | 13.47 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.58 |
| Quick Ratio | 5.27 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.25 |
Financial Efficiency
Return on equity (ROE) is -96.00% and return on invested capital (ROIC) is -107.80%.
| Return on Equity (ROE) | -96.00% |
| Return on Assets (ROA) | -55.00% |
| Return on Capital (ROIC) | -107.80% |
| Revenue Per Employee | $342,602 |
| Profits Per Employee | -$817,159 |
| Employee Count | 226 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, RYTM has paid $564,000 in taxes.
| Income Tax | 564,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +79.89% in the last 52 weeks. The beta is 1.93, so RYTM's price volatility has been higher than the market average.
| Beta (1Y) | 1.93 |
| 52-Week Price Change | +79.89% |
| 50-Day Moving Average | 42.84 |
| 200-Day Moving Average | 33.21 |
| Relative Strength Index (RSI) | 39.67 |
| Average Volume (30 Days) | 602,012 |
Short Selling Information
The latest short interest is 9.74 million, so 16.19% of the outstanding shares have been sold short.
| Short Interest | 9.74M |
| Short Previous Month | 9.20M |
| Short % of Shares Out | 16.19% |
| Short % of Float | 21.64% |
| Short Ratio (days to cover) | 16.42 |
Income Statement
In the last 12 months, RYTM had revenue of $77.43 million and -$184.68 million in losses. Loss per share was -$3.20.
| Revenue | 77.43M |
| Gross Profit | 68.13M |
| Operating Income | -184.36M |
| Pretax Income | -184.11M |
| Net Income | -184.68M |
| EBITDA | -168.46M |
| EBIT | -170.22M |
| Loss Per Share | -$3.20 |
Balance Sheet
The company has $276.17 million in cash and $1.26 million in debt, giving a net cash position of $274.91 million or $4.57 per share.
| Cash & Cash Equivalents | 276.17M |
| Total Debt | 1.26M |
| Net Cash | 274.91M |
| Net Cash Per Share | $4.57 |
| Equity / Book Value | 169.76M |
| Book Value Per Share | 2.82 |
| Working Capital | 253.07M |
Cash Flow
In the last 12 months, operating cash flow was -$136.16 million and capital expenditures -$47,000, giving a free cash flow of -$136.20 million.
| Operating Cash Flow | -136.16M |
| Capital Expenditures | -47,000 |
| Free Cash Flow | -136.20M |
| FCF Per Share | -$2.36 |
Margins
Gross margin is 87.99%, with operating and profit margins of -238.10% and -238.52%.
| Gross Margin | 87.99% |
| Operating Margin | -238.10% |
| Pretax Margin | -237.79% |
| Profit Margin | -238.52% |
| EBITDA Margin | -217.58% |
| EBIT Margin | -219.85% |
| FCF Margin | -175.91% |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.65% |
| Shareholder Yield | -10.65% |
| Earnings Yield | -8.08% |
| FCF Yield | -5.96% |
Analyst Forecast
The average price target for RYTM is $47.20, which is 24.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.20 |
| Price Target Difference | 24.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 73.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 4.11 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.11 |
| Piotroski F-Score | 3 |